REGENXBIO Inc. Stockholders Equity

• REGENXBIO Inc. showed a decrease of -60.4% in Stockholders Equity from 2024 to 2025.
• This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2015: $221.81 million | Q1 2016: $208.60 million | Q2 2016: $196.18 million | Q3 2016: $180.23 million | Q1 2017: $212.90 million | Q2 2017: $211.70 million | Q3 2017: $194.65 million | Q1 2018: $299.34 million | Q2 2018: $317.22 million | Q3 2018: $494.06 million | Q1 2019: $487.05 million | Q2 2019: $494.59 million | Q3 2019: $468.40 million | Q1 2020: $420.15 million | Q2 2020: $397.86 million | Q3 2020: $415.66 million | Q1 2021: $554.50 million | Q2 2021: $507.25 million | Q3 2021: $461.41 million | Q1 2022: $689.67 million | Q2 2022: $630.52 million | Q3 2022: $563.82 million | Q1 2023: $465.14 million | Q2 2023: $405.86 million | Q3 2023: $363.10 million | Q1 2024: $390.67 million | Q2 2024: $348.27 million | Q3 2024: $301.42 million | Q1 2025: $274.20 million | Q2 2025: $213.68 million | Q3 2025: $161.45 million.
• Over the full 14 years of available data (2012 to 2025), REGENXBIO Inc.'s Stockholders Equity has grown by 1,366.4%.
• Historical annual values: Fiscal year 2025: $102.73 million | Fiscal year 2024: $259.65 million | Fiscal year 2023: $311.74 million | Fiscal year 2022: $516.20 million | Fiscal year 2021: $764.30 million | Fiscal year 2020: $377.75 million | Fiscal year 2019: $450.20 million | Fiscal year 2018: $508.85 million | Fiscal year 2017: $183.03 million | Fiscal year 2016: $161.74 million | Fiscal year 2015: $216.81 million | Fiscal year 2014: -$18.29 million | Fiscal year 2013: -$13.92 million | Fiscal year 2012: -$8.11 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026